AU2021249129B2 - Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase - Google Patents

Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase

Info

Publication number
AU2021249129B2
AU2021249129B2 AU2021249129A AU2021249129A AU2021249129B2 AU 2021249129 B2 AU2021249129 B2 AU 2021249129B2 AU 2021249129 A AU2021249129 A AU 2021249129A AU 2021249129 A AU2021249129 A AU 2021249129A AU 2021249129 B2 AU2021249129 B2 AU 2021249129B2
Authority
AU
Australia
Prior art keywords
subject
fenebrutinib
acceptable salt
pharmaceutically acceptable
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021249129A
Other languages
English (en)
Other versions
AU2021249129A1 (en
Inventor
Hideki Garren
Edmond Huatung TENG
Aurelien VIACCOZ
Hans-Christian VON BUEDINGEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of AU2021249129A1 publication Critical patent/AU2021249129A1/en
Application granted granted Critical
Publication of AU2021249129B2 publication Critical patent/AU2021249129B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021249129A 2020-04-03 2021-04-01 Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase Active AU2021249129B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005095P 2020-04-03 2020-04-03
US63/005,095 2020-04-03
US202063051767P 2020-07-14 2020-07-14
US63/051,767 2020-07-14
PCT/US2021/025301 WO2021202825A1 (en) 2020-04-03 2021-04-01 Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
AU2021249129A1 AU2021249129A1 (en) 2022-10-20
AU2021249129B2 true AU2021249129B2 (en) 2026-06-04

Family

ID=75625678

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021249129A Active AU2021249129B2 (en) 2020-04-03 2021-04-01 Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase

Country Status (13)

Country Link
US (1) US12605376B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125906A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520469A (cg-RX-API-DMAC7.html)
KR (1) KR20220163986A (cg-RX-API-DMAC7.html)
CN (1) CN115916205A (cg-RX-API-DMAC7.html)
AU (1) AU2021249129B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177390A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002699A1 (cg-RX-API-DMAC7.html)
IL (1) IL296990A (cg-RX-API-DMAC7.html)
MX (1) MX2022012310A (cg-RX-API-DMAC7.html)
TW (1) TWI907406B (cg-RX-API-DMAC7.html)
WO (1) WO2021202825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899163B (zh) * 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
BR112023021235A2 (pt) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途
WO2024238524A1 (en) * 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
US20210113568A1 (en) * 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
EP3914250A1 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
TWI899163B (zh) 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
National Center for Biotechnology Information. "PubChem Compound Summary for CID 86567195, Fenebrutinib" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Fenebrutinib. *

Also Published As

Publication number Publication date
BR112022019846A2 (pt) 2022-11-22
TW202203925A (zh) 2022-02-01
IL296990A (en) 2022-12-01
JP2023520469A (ja) 2023-05-17
CN115916205A (zh) 2023-04-04
US12605376B2 (en) 2026-04-21
KR20220163986A (ko) 2022-12-12
TWI907406B (zh) 2025-12-11
EP4125906A1 (en) 2023-02-08
AU2021249129A1 (en) 2022-10-20
CL2022002699A1 (es) 2023-03-31
WO2021202825A1 (en) 2021-10-07
CA3177390A1 (en) 2021-10-07
US20230149395A1 (en) 2023-05-18
MX2022012310A (es) 2022-10-27